AETHLON MEDICAL INC (AEMD): Results of Operations and Financial Condition
AETHLON MEDICAL INC (AEMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® Program Conference Call Today at 4:30 p.m. ET SAN DIEGO, August 13, 2026 -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company, today
How this was made
The 30-second read
Why it matters
For traders, the key decision inputs are (1) liquidity and financing timing, (2) whether the Hemopurifier program is progressing through dosing cohorts, and (3) whether operating expense trends are improving enough to extend runway.
Market read
The filing combines financial condition (cash, expenses), a post-quarter equity raise, and early clinical/research progress, which can drive small-cap biotech sentiment and liquidity expectations.
What to watch
The release emphasizes preliminary biomarker signals and accepted publication, but provides no safety/tolerability updates or quantitative response rates, which may temper enthusiasm.
Background
This is an SEC Form 8-K (Item 2.02) with a press release covering fiscal Q1 ended June 30, 2026, plus a corporate update on the Hemopurifier Phase 1 oncology study and Long COVID research.
Ticker impact
Aethlon reported Q1 FY2027 results, disclosed $4.9M cash at June 30, and said it raised about $4.0M post-quarter via a common stock offering.
Likely two-sided reaction: positive for cash raise and continued trial progress, offset by ongoing operating losses and small cash balance.
The filing is a primary disclosure (8-K with earnings/financial condition) and includes concrete liquidity numbers and a new financing event, but it does not provide efficacy endpoints or guidance beyond a 12-month funding belief.
Market effects
Adds incremental datapoints for clinical-stage biotech device platforms, but no direct read-across to specific peers is provided.
No clear regional market linkage beyond general small-cap biotech sentiment.
Clinical activity is in Australia, but the disclosure is company-specific and not a global macro driver.
Counterpoint
The $4.0M gross raise may be dilutive and the company still reports a cash balance of only about $4.9M, so upside may be limited until clearer clinical efficacy emerges.
Key entities
- companyAethlon Medical, Inc.
Nasdaq-listed clinical-stage medical therapeutic company advancing the Hemopurifier investigational platform.
- programHemopurifier®
Investigational extracorporeal device intended to remove enveloped viruses and tumor-derived extracellular vesicles.
- clinical_trialPhase 1 oncology study (Australia)
Company disclosed first participant dosed in the third and final dosing cohort during the quarter.
